Taysha Gene Therapies Quarterly Balance Sheet
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 4.58 +2.00%
Taysha Gene Therapies financial position
As of Jun 30, 2026, Taysha Gene Therapies reported total assets of $470.4 million, up 41.1% from a year earlier against total liabilities of $83.2 million. Shareholders' equity stood at $387.3 million, or 82.3% of assets. The company held $455.4 million in cash and equivalents against $49.3 million of debt, a net cash position of $406.1 million.
The current ratio (current assets divided by current liabilities) was 17.76, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.13.
Summary generated from market data by MetaCap's automated system. Methodology
Taysha Gene Therapies balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 455.41M | 276.58M | 319.77M | 297.34M | 312.76M | 116.59M | 139.04M | 157.69M | 172.74M | 123.98M | 143.94M | 164.28M |
| Total Current Assets | 461.43M | 282.25M | 324.65M | 299.95M | 316.26M | 120.71M | 142.13M | 161.56M | 178.47M | 130.60M | 149.87M | 171.81M |
| Property, Plant & Equipment | 2.41M | 6.45M | 6.74M | 6.80M | 6.96M | 7.24M | 7.49M | 7.61M | 10.51M | 10.69M | 10.83M | 11.17M |
| Total Assets | 470.43M | 300.35M | 343.32M | 316.55M | 333.33M | 138.36M | 160.36M | 180.22M | 200.39M | 153.00M | 172.73M | 195.77M |
| Accounts Payable | 9.16M | 4.56M | 6.28M | 5.44M | 7.71M | 4.33M | 3.59M | 4.93M | 8.72M | 10.38M | 6.37M | 7.52M |
| Total Current Liabilities | 25.98M | 20.10M | 26.55M | 28.63M | 25.35M | 22.56M | 26.23M | 29.34M | 34.18M | 38.64M | 36.76M | 180.45M |
| Long-Term Debt | 49.26M | 48.96M | 50.11M | 50.85M | 41.05M | 42.45M | 43.94M | 42.97M | 37.84M | 40.51M | 40.51M | 38.55M |
| Total Liabilities | 83.17M | 88.41M | 96.38M | 97.56M | 84.60M | 83.30M | 88.84M | 91.42M | 91.53M | 99.15M | 97.79M | 244.88M |
| Shareholders' Equity | 387.27M | 211.94M | 246.94M | 218.99M | 248.73M | 55.06M | 71.53M | 88.80M | 108.87M | 53.85M | 74.94M | -49.11M |
| Retained Earnings | -800.35M | -753.71M | -711.30M | -683.45M | -650.72M | -623.83M | -602.30M | -583.52M | -558.00M | -537.07M | -513.01M | -560.75M |
| Total Debt | 49.26M | 48.96M | 50.11M | 50.85M | 41.05M | 42.45M | 43.94M | 42.97M | 37.84M | 40.51M | 40.51M | 38.55M |
| Net Cash (Debt) | 406.15M | 227.62M | 269.66M | 246.49M | 271.71M | 74.14M | 95.09M | 114.72M | 134.91M | 83.47M | 103.43M | 125.73M |
| Shares Outstanding | 325.30M | 287.28M | 285.05M | 273.92M | 272.73M | 205.05M | 204.94M | 204.94M | 201.38M | 187.02M | 186.96M | 186.96M |
This table shows 12 quarterly periods of Taysha Gene Therapies's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow TSHA's reporting calendar. What is a balance sheet?